PL3600419T3 - Leczenie raka przeciwciałem wiążącym semaforynę-4d w kombinacji ze środkiem epigenetycznie modulującym - Google Patents
Leczenie raka przeciwciałem wiążącym semaforynę-4d w kombinacji ze środkiem epigenetycznie modulującymInfo
- Publication number
- PL3600419T3 PL3600419T3 PL18771465.4T PL18771465T PL3600419T3 PL 3600419 T3 PL3600419 T3 PL 3600419T3 PL 18771465 T PL18771465 T PL 18771465T PL 3600419 T3 PL3600419 T3 PL 3600419T3
- Authority
- PL
- Poland
- Prior art keywords
- semaphorin
- antibody
- cancer
- treatment
- combination
- Prior art date
Links
- 108010056102 CD100 antigen Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102100027744 Semaphorin-4D Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000001973 epigenetic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762473731P | 2017-03-20 | 2017-03-20 | |
| PCT/US2018/022414 WO2018175179A1 (en) | 2017-03-20 | 2018-03-14 | Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3600419T3 true PL3600419T3 (pl) | 2024-02-19 |
Family
ID=63585710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18771465.4T PL3600419T3 (pl) | 2017-03-20 | 2018-03-14 | Leczenie raka przeciwciałem wiążącym semaforynę-4d w kombinacji ze środkiem epigenetycznie modulującym |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11572408B2 (pl) |
| EP (1) | EP3600419B1 (pl) |
| JP (1) | JP7159187B2 (pl) |
| KR (1) | KR102627372B1 (pl) |
| CN (1) | CN110446504B (pl) |
| AU (1) | AU2018237549B2 (pl) |
| BR (1) | BR112019019597A2 (pl) |
| CA (1) | CA3053649A1 (pl) |
| DK (1) | DK3600419T5 (pl) |
| ES (1) | ES2963046T3 (pl) |
| FI (1) | FI3600419T3 (pl) |
| IL (1) | IL268000B2 (pl) |
| MX (1) | MX2019011130A (pl) |
| PL (1) | PL3600419T3 (pl) |
| PT (1) | PT3600419T (pl) |
| SG (1) | SG11201906404RA (pl) |
| WO (1) | WO2018175179A1 (pl) |
| ZA (1) | ZA201904432B (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| ES2935585T3 (es) | 2016-04-22 | 2023-03-08 | Vaccinex Inc | Presentación de proteínas integrales de membrana presentadas sobre viriones con envoltura extracelular de poxvirus |
| MX2019001453A (es) | 2016-08-02 | 2019-06-20 | Vaccinex Inc | Metodos mejorados para producir genotecas de polinucleotidos en virus vacuna/ celulas eucariotas. |
| US20220008383A1 (en) * | 2018-11-13 | 2022-01-13 | Amy Yee | Compositions and methods of enhancing immunotherapies |
| EP3693380A1 (en) * | 2019-02-11 | 2020-08-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Dual inhibition of plexin-b1 and plexin-b2 |
| CA3152371A1 (en) | 2019-08-01 | 2021-02-04 | Vaccinex, Inc. | Combined inhibition of semaphorin-4d and tgf.beta. and compositions therefor |
| CN114601929B (zh) * | 2022-05-03 | 2023-07-14 | 安徽省立医院(中国科学技术大学附属第一医院) | IIa类HDAC抑制剂TMP269在ARID1A缺失型肝癌中的应用 |
| WO2025019301A1 (en) * | 2023-07-14 | 2025-01-23 | Wake Forest University Health Sciences | Inhibition of nsun2 for the treatment of cancer |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| AU6852594A (en) | 1993-06-03 | 1995-01-03 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20030232419A1 (en) * | 2002-02-04 | 2003-12-18 | Kolodkin Alex L. | Molecules interacting with CASL (MICAL) polynucleotides, polypeptides, and methods of using the same |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| US7317601B2 (en) | 2004-07-29 | 2008-01-08 | United Microelectronics Corp. | Electrostatic discharge protection device and circuit thereof |
| US7919594B2 (en) * | 2007-02-14 | 2011-04-05 | Vaccinex, Inc. | Human anti-CD100 antibodies |
| WO2009015382A2 (en) * | 2007-07-26 | 2009-01-29 | Alba Therapeutics Corporation | Novel peptides that enhance tight junction permeability |
| RU2488591C2 (ru) | 2007-09-26 | 2013-07-27 | Маунт Синай Скул Оф Медсин | Аналоги азацитидина и их применение |
| DK2427212T3 (en) | 2009-05-08 | 2017-12-04 | Vaccinex Inc | ANTI-CD100 ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| US9289415B2 (en) | 2011-09-01 | 2016-03-22 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| CN105102480B (zh) * | 2012-12-24 | 2019-04-16 | 艾伯维公司 | 催乳素受体结合蛋白及其用途 |
| CA2916245C (en) * | 2013-06-25 | 2023-01-24 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| TWI688401B (zh) * | 2013-09-13 | 2020-03-21 | 美商安進公司 | 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合 |
| NZ630892A (en) * | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| AU2015289922A1 (en) * | 2014-07-15 | 2017-02-16 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
| JP2017535528A (ja) * | 2014-10-03 | 2017-11-30 | ノバルティス アーゲー | 組み合わせ治療 |
-
2018
- 2018-03-14 BR BR112019019597A patent/BR112019019597A2/pt unknown
- 2018-03-14 DK DK18771465.4T patent/DK3600419T5/da active
- 2018-03-14 CA CA3053649A patent/CA3053649A1/en active Pending
- 2018-03-14 US US16/496,286 patent/US11572408B2/en active Active
- 2018-03-14 ES ES18771465T patent/ES2963046T3/es active Active
- 2018-03-14 MX MX2019011130A patent/MX2019011130A/es unknown
- 2018-03-14 JP JP2019551607A patent/JP7159187B2/ja active Active
- 2018-03-14 PT PT187714654T patent/PT3600419T/pt unknown
- 2018-03-14 KR KR1020197025542A patent/KR102627372B1/ko active Active
- 2018-03-14 AU AU2018237549A patent/AU2018237549B2/en active Active
- 2018-03-14 FI FIEP18771465.4T patent/FI3600419T3/fi active
- 2018-03-14 CN CN201880019512.9A patent/CN110446504B/zh active Active
- 2018-03-14 PL PL18771465.4T patent/PL3600419T3/pl unknown
- 2018-03-14 SG SG11201906404RA patent/SG11201906404RA/en unknown
- 2018-03-14 WO PCT/US2018/022414 patent/WO2018175179A1/en unknown
- 2018-03-14 EP EP18771465.4A patent/EP3600419B1/en active Active
-
2019
- 2019-07-05 ZA ZA2019/04432A patent/ZA201904432B/en unknown
- 2019-07-11 IL IL268000A patent/IL268000B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110446504B (zh) | 2024-07-26 |
| US11572408B2 (en) | 2023-02-07 |
| KR102627372B1 (ko) | 2024-01-19 |
| AU2018237549A1 (en) | 2019-08-01 |
| DK3600419T5 (en) | 2024-05-27 |
| DK3600419T3 (en) | 2023-11-06 |
| SG11201906404RA (en) | 2019-08-27 |
| ES2963046T3 (es) | 2024-03-25 |
| US20210179708A1 (en) | 2021-06-17 |
| KR20190126311A (ko) | 2019-11-11 |
| EP3600419A4 (en) | 2020-12-02 |
| MX2019011130A (es) | 2019-11-05 |
| PT3600419T (pt) | 2023-11-16 |
| IL268000A (en) | 2019-09-26 |
| RU2019122330A (ru) | 2021-04-21 |
| JP2020511493A (ja) | 2020-04-16 |
| EP3600419A1 (en) | 2020-02-05 |
| FI3600419T3 (fi) | 2023-11-08 |
| CA3053649A1 (en) | 2018-09-27 |
| AU2018237549B2 (en) | 2024-08-01 |
| WO2018175179A1 (en) | 2018-09-27 |
| JP7159187B2 (ja) | 2022-10-24 |
| BR112019019597A2 (pt) | 2020-04-14 |
| IL268000B2 (en) | 2023-06-01 |
| ZA201904432B (en) | 2023-12-20 |
| RU2019122330A3 (pl) | 2021-10-20 |
| EP3600419B1 (en) | 2023-08-09 |
| CN110446504A (zh) | 2019-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268000A (en) | Cancer treatment with semphorin-4d antibody in combination with an epigenetic modulator factor | |
| ZA201904695B (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| IL261468A (en) | Uterine cancer treatments | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| IL248455B (en) | igf-1r antibody-drug conjugate and its use for cancer treatment | |
| SG11201701035SA (en) | Cancer diagnosis and therapy | |
| GB201706451D0 (en) | Cancer treatment | |
| HUE062453T2 (hu) | Rákbetegség kezelése | |
| ZA201802618B (en) | Anti-cd43 antibody and use thereof for cancer treatment | |
| IL261648A (en) | Cinnolin-4-amine compounds and their use in treating cancer | |
| IL274626A (en) | Cancer treatment | |
| GB201707864D0 (en) | Platinum-reistant cancer treatment | |
| EP3380468B8 (en) | Bis-pyridazine compounds and their use in treating cancer | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| IL280421A (en) | Cancer treatment by antibody | |
| HK40097706A (en) | Combinations of imetelstat and venetoclax for use in the treatment of haematological cancer | |
| GB2578008B (en) | 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment | |
| GB201813138D0 (en) | Cancer treatment with an antibody | |
| GB201720533D0 (en) | Cancer treatments | |
| GB201713852D0 (en) | Cancer treatment |